from dataclasses import dataclass
from typing import Optional
from openai import OpenAI
from varpubs.pubmed_db import PubmedArticle


@dataclass
class Settings:
    api_key: str
    role: str
    model: str = "medgemma-27b-it"
    base_url: Optional[str] = None
    max_new_tokens: int = 500
    temperature: float = 0.1


@dataclass
class PubmedSummarizer:
    settings: Settings

    @property
    def client(self) -> OpenAI:
        return OpenAI(api_key=self.settings.api_key, base_url=self.settings.base_url)

    def summarize(self, article: PubmedArticle, term: str) -> str:
        instruction_text = f"You are an {self.settings.role}."
        input_text = f"Concisely summarize the information in the following text regarding {term} in at most three sentences for your colleagues:\n\nTitle: {article.title}\n\n{article.abstract}"

        response = self.client.chat.completions.create(
            model=self.settings.model,
            messages=[
                {"role": "system", "content": instruction_text},
                {"role": "user", "content": input_text},
            ],
            temperature=self.settings.temperature,
            max_tokens=self.settings.max_new_tokens,
        )
        return str(response.choices[0].message.content)

    def validate_summary(self, abstract: str, summary: str) -> bool:
        few_shots = [
            {
                "abstract": "While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAFV600E CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone. Single-cell RNA sequencing of 23 paired pretreatment and day 15 on-treatment tumor biopsies revealed greater induction of tumor cell-intrinsic immune programs and more complete MAPK inhibition in patients with better clinical outcome. Immune program induction in matched patient-derived organoids correlated with the degree of MAPK inhibition. These data suggest a potential tumor cell-intrinsic mechanism of cooperativity between MAPK inhibition and immune response, warranting further clinical evaluation of optimized targeted and immune combinations in CRC.",
                "summary": "In BRAFV600E colorectal cancer, combining PD-1, BRAF, and MEK inhibitors demonstrated a 24.3% overall response rate and improved durability compared to historical BRAF-targeted therapies. Single-cell RNA sequencing and organoid models revealed that better responses were linked to stronger MAPK inhibition and induction of tumor-intrinsic immune programs. These findings suggest a cooperative mechanism between MAPK suppression and immune activation in BRAFV600E CRC, supporting further clinical evaluation.",
                "reason": "The study's findings support this claim.",
                "validation": True,
            },
            {
                "abstract": """Purpose: BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival (OS) and objective response rate (ORR; by blinded central review) versus standard of care. The purpose of this analysis was to report updated efficacy and safety data.

                Methods: In this open-label, phase III trial, 665 patients with BRAF V600E-mutant mCRC were randomly assigned 1:1:1 to receive triplet, doublet, or control. Primary end points were OS and independently reviewed ORR comparing triplet to control. OS for doublet versus control was a key secondary end point. Updated analyses include 6 months of additional follow-up and ORR for all randomized patients.

                Results: Patients received triplet (n = 224), doublet (n = 220), or control (n = 221). Median OS was 9.3 months (95% CI, 8.2 to 10.8) for triplet and 5.9 months (95% CI, 5.1 to 7.1) for control (hazard ratio [HR], 0.60 [95% CI, 0.47 to 0.75]). Median OS for doublet was 9.3 months (95% CI, 8.0 to 11.3) (HR v control, 0.61 [95% CI, 0.48 to 0.77]). Confirmed ORR was 26.8% (95% CI, 21.1% to 33.1%) for triplet, 19.5% (95% CI, 14.5% to 25.4%) for doublet, and 1.8% (95% CI, 0.5% to 4.6%) for control. Adverse events were consistent with the prior primary analysis, with grade â‰¥ 3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet, and control, respectively.

                Conclusion: In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the metastatic setting compared with standard chemotherapy. Based on the primary and updated analyses, encorafenib plus cetuximab is a new standard care regimen for previously treated patients with BRAF V600E mCRC.""",
                "summary": "In 723 (524 male, 199 female) patients with BRAF V600E-mutant metastatic colorectal cancer, the BEACON CRC phase III trial showed that encorafenib plus cetuximab, with or without binimetinib, significantly improved overall survival and objective response rate compared to standard radiotherapy. Median overall survival was approximately 9.3 months for both the doublet and triplet regimens, versus 5.9 months for control. These results support encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E mCRC patients.",
                "reason": "The original abstract did not provide the number of patients in this study nor how many of them were male and female. Additionally, the summary incorrectly states that survival was compared against radiotherapy, whereas the abstract clearly specifies that the control arm received chemotherapy.",
                "validation": False,
            },
        ]
        few_shot_text = [
            f"Abstract: {f['abstract']}\n\nSummary: {f['summary']}\n\nReason: {f['reason']}\n\nValidation: {f['validation']}"
            for f in few_shots
        ]
        instruction_text = (
            "You are a scientific reviewer. "
            "Your task is to check whether the summary is factually accurate based ONLY on the abstract. "
            f"Examples:\n\n{few_shot_text}\n\n"
            "If any detail is incorrect, misleading, or cannot be confirmed, respond with 'False'. "
            "Otherwise, respond with 'True'. Respond with exactly one word: 'True' or 'False'."
        )

        input_text = (
            f"Abstract:\n{abstract}\n\n"
            f"Summary:\n{summary}\n\n"
            f"Is the summary factually accurate based on the abstract?"
        )

        response = self.client.chat.completions.create(
            model=self.settings.model,
            messages=[
                {"role": "system", "content": instruction_text},
                {"role": "user", "content": input_text},
            ],
            temperature=1,
            max_tokens=5,
        )

        answer = str(response.choices[0].message.content).strip().lower()
        return "true" in answer
